메뉴 건너뛰기




Volumn 27, Issue 4, 2013, Pages 982-985

Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; LETTER; MYELOID LEUKEMIA; PATHOGENESIS; PRIORITY JOURNAL; SOMATIC MUTATION; SPLICEOSOME;

EID: 84876131053     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.267     Document Type: Letter
Times cited : (22)

References (15)
  • 4
    • 84863337757 scopus 로고    scopus 로고
    • Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells
    • Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012; 21: 430-446.
    • (2012) Cancer Cell , vol.21 , pp. 430-446
    • Tsai, H.C.1    Li, H.2    Van Neste, L.3    Cai, Y.4    Robert, C.5    Rassool, F.V.6
  • 5
    • 70350720044 scopus 로고    scopus 로고
    • MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
    • Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy TE, Paietta E et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009; 114: 3448-3458.
    • (2009) Blood , vol.114 , pp. 3448-3458
    • Figueroa, M.E.1    Skrabanek, L.2    Li, Y.3    Jiemjit, A.4    Fandy, T.E.5    Paietta, E.6
  • 6
    • 60849089645 scopus 로고    scopus 로고
    • Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
    • Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O'Keefe C et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009; 113: 1315-1325.
    • (2009) Blood , vol.113 , pp. 1315-1325
    • Jiang, Y.1    Dunbar, A.2    Gondek, L.P.3    Mohan, S.4    Rataul, M.5    O'Keefe, C.6
  • 7
    • 77956870600 scopus 로고    scopus 로고
    • Promoter methylation of DAPK1. E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms
    • Greco M, D'Alò F, Scardocci A, Criscuolo M, Fabiani E, Guidi F et al. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. Blood Cells Mol Dis 2010; 45: 181-185.
    • (2010) Blood Cells Mol Dis , vol.45 , pp. 181-185
    • Greco, M.1    D'Alò, F.2    Scardocci, A.3    Criscuolo, M.4    Fabiani, E.5    Guidi, F.6
  • 9
    • 83455234787 scopus 로고    scopus 로고
    • Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
    • Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011; 118: 6239-6246.
    • (2011) Blood , vol.118 , pp. 6239-6246
    • Malcovati, L.1    Papaemmanuil, E.2    Bowen, D.T.3    Boultwood, J.4    Della Porta, M.G.5    Pascutto, C.6
  • 10
    • 84856477048 scopus 로고    scopus 로고
    • Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia
    • Fried I, Bodner C, Pichler MM, Lind K, Beham-Schmid C, Quehenberger F et al. Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia. Haematologica 2012; 97: 246-250.
    • (2012) Haematologica , vol.97 , pp. 246-250
    • Fried, I.1    Bodner, C.2    Pichler, M.M.3    Lind, K.4    Beham-Schmid, C.5    Quehenberger, F.6
  • 11
    • 84857232561 scopus 로고    scopus 로고
    • Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia
    • Ottone T, Cicconi L, Hasan SK, Lavorgna S, Divona M, Voso MT et al. Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia. Leuk Res 2012; 36: 474-478.
    • (2012) Leuk Res , vol.36 , pp. 474-478
    • Ottone, T.1    Cicconi, L.2    Hasan, S.K.3    Lavorgna, S.4    Divona, M.5    Voso, M.T.6
  • 12
    • 77954658823 scopus 로고    scopus 로고
    • IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic-or blastphase essential thrombocythemia, polycythemia vera or myelofibrosis
    • Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic-or blastphase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010; 24: 1302-1309.
    • (2010) Leukemia , vol.24 , pp. 1302-1309
    • Tefferi, A.1    Lasho, T.L.2    Abdel-Wahab, O.3    Guglielmelli, P.4    Patel, J.5    Caramazza, D.6
  • 13
    • 84861082246 scopus 로고    scopus 로고
    • Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome
    • Zhang SJ, Rampal R, Manshouri T, Patel J, Mensah N, Kayserian A et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 2012; 119: 4480-4485.
    • (2012) Blood , vol.119 , pp. 4480-4485
    • Zhang, S.J.1    Rampal, R.2    Manshouri, T.3    Patel, J.4    Mensah, N.5    Kayserian, A.6
  • 14
    • 20144389274 scopus 로고    scopus 로고
    • Acute leukemia in polycythemia vera: An analysis of 1638 patients enrolled in a prospective observational study
    • Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005; 105: 2664-2670.
    • (2005) Blood , vol.105 , pp. 2664-2670
    • Finazzi, G.1    Caruso, V.2    Marchioli, R.3    Capnist, G.4    Chisesi, T.5    Finelli, C.6
  • 15
    • 80053945428 scopus 로고    scopus 로고
    • Treatment of polycythemia vera with hydroxyurea and pipobroman: Final results of a randomized trial initiated in 1980
    • Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 2011; 29: 3907-3913.
    • (2011) J Clin Oncol , vol.29 , pp. 3907-3913
    • Kiladjian, J.J.1    Chevret, S.2    Dosquet, C.3    Chomienne, C.4    Rain, J.D.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.